360 related articles for article (PubMed ID: 17476171)
1. Bisphosphonates. A cornerstone of osteoporosis treatment.
Mayo Clin Womens Healthsource; 2007 May; 11(5):1-2. PubMed ID: 17476171
[No Abstract] [Full Text] [Related]
2. Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion.
Fitzpatrick SG; Stavropoulos MF; Bowers LM; Neuman AN; Hinkson DW; Green JG; Bhattacharyya I; Cohen DM
J Oral Maxillofac Surg; 2012 Feb; 70(2):325-30. PubMed ID: 21723015
[No Abstract] [Full Text] [Related]
3. Osteonecrosis of the jawbones in 2 osteoporosis patients treated with nitrogen-containing bisphosphonates: osteonecrosis reduction replacing NBP with non-NBP (etidronate) and rationale.
Yamaguchi K; Oizumi T; Funayama H; Kawamura H; Sugawara S; Endo Y
J Oral Maxillofac Surg; 2010 Apr; 68(4):889-97. PubMed ID: 20056305
[No Abstract] [Full Text] [Related]
4. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Iwamoto J; Takeda T; Sato Y
Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
[TBL] [Abstract][Full Text] [Related]
5. Safety considerations with bisphosphonates for the treatment of osteoporosis.
Strampel W; Emkey R; Civitelli R
Drug Saf; 2007; 30(9):755-63. PubMed ID: 17722968
[TBL] [Abstract][Full Text] [Related]
6. Osteonecrosis of the jaw: new developments in an old disease.
Khan A
J Rheumatol; 2008 Apr; 35(4):547-9. PubMed ID: 18398947
[No Abstract] [Full Text] [Related]
7. What is the optimal duration of bisphosphonate therapy?
Ott SM
Cleve Clin J Med; 2011 Sep; 78(9):619-30. PubMed ID: 21885695
[TBL] [Abstract][Full Text] [Related]
8. Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.
Bobba RS; Beattie K; Parkinson B; Kumbhare D; Adachi JD
Drug Saf; 2006; 29(12):1133-52. PubMed ID: 17147460
[TBL] [Abstract][Full Text] [Related]
9. [Jaw osteonecrosis induced by oral biphosphonates: 12 cases].
Barrier A; Lescaille G; Rigolet A; Descroix V; Goudot P; Ruhin B
Rev Stomatol Chir Maxillofac; 2010 Sep; 111(4):196-202. PubMed ID: 20810140
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.
Bilezikian JP
Am J Med; 2009 Feb; 122(2 Suppl):S14-21. PubMed ID: 19187808
[TBL] [Abstract][Full Text] [Related]
11. [Bisphosphonates for osteoporosis].
Narusawa K; Nakamura T
Nihon Rinsho; 2007 Nov; 65 Suppl 9():311-5. PubMed ID: 18161123
[No Abstract] [Full Text] [Related]
12. [Osteoporosis treatment: choices and options].
Reginster JY
Pol Arch Med Wewn; 2007 Jul; 117(7):283-4. PubMed ID: 17966592
[No Abstract] [Full Text] [Related]
13. [Inflammation of the jaws during treatment with bisphosphonates].
Bartl R
Dtsch Med Wochenschr; 2011 Oct; 136(41):2109-10. PubMed ID: 21971888
[No Abstract] [Full Text] [Related]
14. RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction.
Curtis JR; Westfall AO; Cheng H; Saag KG; Delzell E
Osteoporos Int; 2009 Jun; 20(6):973-8. PubMed ID: 18946630
[TBL] [Abstract][Full Text] [Related]
15. By the way, doctor. I'm 60 and have osteoporosis. My doctor is recommending Fosamax, but I'm concerned about jawbone problems. Are there any other drugs I can take?
Robb-Nicholson C
Harv Womens Health Watch; 2006 Dec; 14(4):8. PubMed ID: 17299880
[No Abstract] [Full Text] [Related]
16. Bisphosphonate-associated atypical subtrochanteric femur fractures in the older patient.
Gopal GK; Tam KL; Krishnan SP; Maddern IL
N Z Med J; 2014 Feb; 127(1389):81-5. PubMed ID: 24548959
[TBL] [Abstract][Full Text] [Related]
17. Role of alendronate and risedronate in preventing and treating osteoporosis.
Peters ML; Leonard M; Licata AA
Cleve Clin J Med; 2001 Nov; 68(11):945-51. PubMed ID: 11718433
[TBL] [Abstract][Full Text] [Related]
18. Fracture prevention in postmenopausal women.
Mosekilde L; Vestergaard P; Langdahl B
Clin Evid; 2006 Jun; (15):1543-60. PubMed ID: 16973058
[No Abstract] [Full Text] [Related]
19. Osteochemonecrosis of jaws and bisphosphonates.
Khosa AD; Nayyar MS; Beirne JC
Ir Med J; 2007 Mar; 100(3):410-1. PubMed ID: 17491545
[TBL] [Abstract][Full Text] [Related]
20. Unusual mid-shaft fractures during long-term bisphosphonate therapy.
Odvina CV; Levy S; Rao S; Zerwekh JE; Rao DS
Clin Endocrinol (Oxf); 2010 Feb; 72(2):161-8. PubMed ID: 19302584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
